Assignment 4: Genomic Health Success Story

Frank Urena BMI 598 , Biomedical Commercialization
Assignment 4, Genomic Health.

• Could the Genomic Health success story could be repeated today? What current factors do you believe would have the most impact on your opinion?
• It can, and it will, driven by the epigenome project (http://www.epigenome.org/) , and the improvements in information access, there still many areas of genomic health for exploration and discovery. Since 2016 medical school curriculums have been adapted to incorporate molecular and genomic medicine, this will create a whole generation of medical providers eager to adopt genetic diagnostic, and genetic determined treatments towards personalized medicine.
•
•
•
• What are the seminal differences between Genomic

Absolutely, since every day we find more and more about the molecular mechanism of these diseases, is well known that a mutation on the ccr5 receptor makes certain people resistant to HIV infection (Nature.com, 2017). This sort of information can help to develop better ways to both treat and diagnose infectious diseases, and with the advancements in other areas such as neuro science, the options for the expansions of these stepchildren are boundless.
•
• If so, how would companies in these other areas compete for investment dollars?
They must show innovation, market interest, and some manner clinical benefit over the current standard of care for the given pathology. As shown in the lecture, before genetic profiling breat cancer patients where receiving chemotherapy as a one size fits all regime, now is known that is not necessary or effective for some members of this population. This information readjusts the health economics of breast cancer treatment, and was probably the selling point for this subject of genomic health. The same cost / benefit should be shown in other to be competitive/ attractive to investors, when repurposing the technology for other